<DOC>
	<DOCNO>NCT01081158</DOCNO>
	<brief_summary>Assessment Safety , Tolerability , Pharmacokinetics Pharmacodynamics SCH 900518 Naive Treatment-Experienced Subjects Infected With Hepatitis C Virus Genotype 1 ( Protocol No . P04695 )</brief_summary>
	<brief_title>Safety , Tolerability , PK PD SCH 900518 Naive Treatment-Experienced Subjects Infected With HCV Genotype 1 ( Protocol No . P04695 )</brief_title>
	<detailed_description />
	<mesh_term>Hepatitis</mesh_term>
	<mesh_term>Hepatitis C</mesh_term>
	<mesh_term>Hepatitis C , Chronic</mesh_term>
	<mesh_term>Ritonavir</mesh_term>
	<mesh_term>Peginterferon alfa-2b</mesh_term>
	<mesh_term>Interferon-alpha</mesh_term>
	<criteria>Subject infect HCV genotype 1 ( subtype ) virus : treatment na√Øve ( eg . interferon ribavirin ) ; treatment experience ( nonresponder relapser ) : subject receive interferon base therapy continue detectable HCV RNA level end followup , subject attain 2 log decline HCV RNA level ~12 week discontinue treatment , subject detectable viral load treatment detectable viral load post treatment . Subject acceptable medical history , physical examination , clinical laboratory evaluation consistent CHC , compensate liver disease , associate disease ( diabetes , hypertension , etc ) . Subjects HCV RNA viral load &gt; 10^5 copies/mL equivalent international unit BMI 18 40 kg/m^2 , men woman , age 1865 year inclusive Female must nonlactating negative pregnancy test Screening Day 1 either nonchildbearing potential childbearing potential , must practice effective doublebarrier contraceptive method least 2 week prior Day 1 30 day study completion . Male must willing practice barrier contraception Day 1 3 month follow treatment SCH 900518 . Subject must ECG record show clinically significant finding Screening . Subject chronic stable hemophilia may enroll Subject stable methadone treatment may enroll study ( evaluation investigator include history stable clinical management &gt; 3 month ) . Subject significant acute chronic medical illness stable control medication ( exclude prohibit medication ) . Subject receive organ transplant . Subject evidence decompensated liver disease physical exam ( encephalopathy , ascites , caput medusa , etc ) . Subject anytime receive HCV NS3specific protease inhibitor . Subject platelet count &lt; 80,000/mm^3 ( confirm repeat analysis ) Screening . Subject serum hemoglobin &lt; 10.0 g/dL ( confirm repeat analysis ) Screening . Subject serum AST /ALT value &gt; 5 x ULN ( confirm repeat analysis ) Screening . Subject serum alkaline phosphatase value &gt; 2 x ULN ( confirm repeat analysis ) Screening . Two follow criterion ( confirm repeat analysis ) Screening : Total serum bilirubin &gt; 2.0 mg/dL . Serum albumin &lt; 3.5 g/dL . INR &gt; 1.7 ( exception hemophiliac ) . Subject neutrophil count &lt; 1,000/mm^3 ( confirm repeat analysis ) Screening . Creatinine clearance ( estimate method Cockcroft Gault ) less 50 mL/min Screening . Subject history clinically significant local systemic infectious disease within 1 week prior screening ( HCVinfection ) . Male subject whose female partner intend become pregnant within 3 month study . Subject positive HIV antibody hepatitis B surface antigen . Subject clinically significant allergy intolerance food drug , know suspected hypersensitivity ingredient investigational product . Subject clinically significant history autoimmune hepatitis . Subject use investigational drug donate blood within 30 day prior study drug administration . Subject receive following treatment : know inhibitor CYP3A4 metabolism ( 2 week prior randomization ) , know inducer CYP3A4 metabolism ( 2 week prior randomization ) treatment HCV infection ( 1 month prior randomization )</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>65 Years</maximum_age>
	<verification_date>February 2015</verification_date>
</DOC>